|Bid||25.80 x 0|
|Ask||23.37 x 0|
|Day's Range||25.02 - 25.88|
|52 Week Range||13.56 - 26.60|
|Beta (5Y Monthly)||0.48|
|PE Ratio (TTM)||82.35|
|Forward Dividend & Yield||0.23 (0.90%)|
|Ex-Dividend Date||Feb. 12, 2020|
|1y Target Est||12.43|
The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma
Shareholder rights law firm Robbins LLP reminds investors that it is investigating whether certain officers and directors of ResMed Inc. (NYSE: RMD) breached their fiduciary duties to shareholders. ResMed develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing.
Digital inhaler data reveals an increased use of rescue inhalers for asthma symptoms due to short-term ozone exposure, even below EPA ozone levels.
Last week, you might have seen that ResMed Inc. (NYSE:RMD) released its quarterly result to the market. The early...
SnapWorx's complementary capabilities increase workflow automation for HMEs, saving time on patient interaction and document retrieval.
ResMed Inc. (NYSE: RMD) (ASX: RMD), a world-leading digital health company, today announced results for its quarter ended December 31, 2019.
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against certain officers and directors of ResMed, Inc. (NYSE: RMD) on behalf of long-term stockholders.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2020 on Thursday, January 30, 2020, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.
ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 38th Annual J.P. Morgan Annual Healthcare Conference on Monday, January 13, 2020, beginning at approximately 8:30 a.m. (Pacific Standard Time) at Westin St. Francis in San Francisco, CA.
Globus Medical, Inc. (GMED), a leading musculoskeletal solutions company, today announced the appointment of Robert Douglas to the Company’s Board of Directors, and the departure of Board member Kurt Wheeler, effective December 11, 2019. Mr. Wheeler has assumed a role that precludes him from serving on public company Boards. Mr. Douglas has nearly thirty years of experience in medical device technology, with particular expertise in digital health.
Examining ResMed Inc.'s (NYSE:RMD) past track record of performance is a useful exercise for investors. It allows us...
ResMed gapped up out of a downward-sloping flat base, surging on earnings. The maker of sleep apnea products reported better-than-expected earnings growth and the third straight quarter of slowly accelerating revenue growth.